Elimination of HIV-1 requires clearance and removal of integrated proviral DNA from infected cells and tissues. Here, sequential long-acting slow-effective release antiviral therapy (LASER… Read More »HIV publication relevance
The complete platform/service allows TCS to carry out any histological study from our advanced human immune system mouse models’ tissues. Numerous applications are offered: Standard… Read More »New IHC platform is now available at TransCure
BMS and Viiv are developing a Multi-specific inhibitor of HIV entry. In this paper, they demonstrate that a long-acting antiretroviral could provide a useful… Read More »TransCure bioServices involved in BMS and ViiV results
This Preclinical Model has a Fully Human Immune System for Vaccine Development Read the full article Full human immune system mouse models have a… Read More »They talk about us in Labiotech – Vaccine/Immunization
in vivo imaging is available at TransCure bioServices Equipped with the Newton 7.0 Bioluminescence imaging system, we can monitor, in a living animal, orthotopic,… Read More »Acquisition of the Newton 7.0 Bioluminescence imaging system
What services is TransCure bioServices offering? Who are its clients? What are its achievements? What are its news goals and new challenges with its… Read More »TransCure’s interview in the ECO Savoie Mont-Blanc
New financing round will enable the company to accelerate its growth and expand its international services offers. TransCure bioServices (France), a one-stop-shop preclinical services… Read More »TransCure bioServices Raises €2,5M Funding
Champions Oncology, Inc. (NASDAQ: CSBR) signs a strategic partnership with TransCure bioServices SAS This newly signed partnership combines Champions’ patient sourced cancer models with… Read More »Champions Oncology, Inc. (NASDAQ: CSBR) signs a strategic partnership with TransCure bioServices SAS
TransCure bioServices SAS was selected for the SME instruments call-to-offer Phase 1 with 273 companies out of 2,822 applicants. The first funding (50k€) awarded… Read More »TransCure’s proposal for Horizon 2020 has been selected by the European Research & Innovation funding program
INSERM publishes first in vivo proof of concept of an engineered Chimeric Antigen Receptor T cell directed against IL-1RAP expressed by leukemia stem cells… Read More »TransCure bioServices involved in INSERM results
